Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.40.5 today, marking a significant milestone in its recent price trajectory. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures and valuation concerns.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.42.01 on 9 March 2026, marking a significant price level amid ongoing market pressures and company-specific factors. The stock underperformed its sector and broader indices, reflecting persistent challenges in its valuation and performance metrics.

Zenotech Laboratories Ltd’s shares touched a fresh 52-week low of Rs.42.05 today, marking a significant decline amid continued underperformance relative to its sector and benchmark indices. The stock has now recorded losses over four consecutive trading sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.43 today, marking a significant price level for the pharmaceutical and biotechnology company amid a broader market environment that saw mixed movements.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.43 today, marking a significant price level for the pharmaceutical and biotechnology company amid a series of recent declines and ongoing market pressures.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 16 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with the latest insights into its performance and outlook.

Zenotech Laboratories Ltd’s share price declined to a fresh 52-week low of Rs.43.01 on 28 Jan 2026, marking a significant milestone in the stock’s recent performance amid broader market gains.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.43.01 on 28 Jan 2026, marking a significant price level for the pharmaceutical and biotechnology company amid ongoing market pressures and company-specific factors.

Zenotech Laboratories Ltd has demonstrated a notable financial turnaround in the quarter ended December 2025, shifting from a negative to a positive growth trajectory. Key metrics such as profit before tax, net sales, and earnings per share have all reached their highest levels in recent quarters, signalling a potential stabilisation in the company’s performance within the Pharmaceuticals & Biotechnology sector.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Zenotech Laboratories Limited, a micro-cap pharmaceutical company specialising in generic injectables for oncology and anaesthesiology, reported a net loss of ₹0.84 crores in Q2 FY26, a sharp reversal from the ₹0.99 crores profit posted in Q1 FY26. The unexpected loss came despite revenue growth of 18.40% quarter-on-quarter, primarily driven by an extraordinary tax charge of ₹2.09 crores representing a staggering 165.87% tax rate. The stock, currently trading at ₹46.50 with a market capitalisation of ₹276.00 crores, has declined 0.70% over the past week and remains in a bearish technical trend.

Zenotech Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid ongoing financial headwinds. While the company continues to face significant profitability pressures and valuation concerns, recent technical trend improvements have prompted a more cautious but less negative outlook from analysts.

Zenotech Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 July 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.